CClinicalTrials.gg
TerminatedNCT03270202HUNT4-PAIUpdated Nov 30, 2018

Wearable Devices to Promote Physical Activity

An interventional study of PAI group and Usual care in Cardiovascular Diseases, sponsored by Norwegian University of Science and Technology. Terminated at 1 site in Norway. Open to participants aged 23 Years and older. Per ClinicalTrials.gov, last updated 2018-11-30.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Prevention

Why this study was terminated
discontinuation of financial support
Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
23 Years and older
Sex
All
01

Study summary

This study evaluates the effect of a new wearable device, that measures physical activity level based on heart rates, on relevant health outcomes including cardiorespiratory fitness. Half of participants will be instructed in using the Mio Slice wristband, while the other half will be requested to follow today's recommendations for physical activity.

Read the detailed description

Two critical challenges precluding the full potential of physical activity in preventive healthcare are: 1) The majority of people are not sufficiently active, and 2) there is a lack of large, long-term intervention studies documenting the effect of personalized activity and improved health in the population. Using HUNT data an algorithm called Personal Activity Intelligence (PAI) has been developed. PAI was integrated in a smartphone application and user friendly wristband (Mio Slice), that measures heart rate continuously and estimates an individual threshold for total physical activity (defined as 100 weekly PAI) that is associated with reduced risk of cardiovascular disease and mortality. The primary aim of the study is to reveal whether using the wristband will increase cardiorespiratory fitness, determined by maximal oxygen uptake, after 4 months among low-fit participants. The secondary aims includes the effect on reversing cardiovascular risk factors, cardiac structure and function, adherence to physical activity and identification of barriers after 16 weeks and 1 year.

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • Exercise
  • Cardiorespiratory fitness
  • Risk factors
  • Monitoring, physiologic
  • Monitoring, ambulatory
  • Prognosis
  • Norway
03

Who can participate

Ages eligible
23 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participated in HUNT 3 and HUNT 4 Fitness Study
  • VO2peak in HUNT4 in the lowest sex- and age-specific tertile.

Exclusion criteria

Exclusion Criteria:

  • Illness or disabilities that preclude completion of the study or make exercise contraindicated
  • uncontrolled hypertension, arrhythmias or angina
  • heart failure
  • primary pulmonary hypertension
  • diagnosed dementia
  • chronic communicable infectious diseases
  • participation in conflicting interventions
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    PAI group

    Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.

    Behavioral: PAI group · Behavioral: Usual care

  • Active comparator
    Usual care

    Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.

    Behavioral: Usual care

Interventions

  • BehavioralPAI group

    * physical activity defined as 100 weekly PAI during 1 year * smartphone application and a user-friendly activity wristband (Mio PAI Slice)

  • BehavioralUsual care

    Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.

05

What researchers measure

Primary outcomes

  1. Peak oxygen uptake (VO2peak)

    Measured by ergospirometry during a maximal treadmill protocol to exhaustion

    Time frame: 16 weeks

Secondary outcomes

  1. Peak oxygen uptake (VO2peak)

    Measured by ergospirometry during a maximal treadmill protocol to exhaustion

    Time frame: 1 year

  2. Cardiovascular risk profile (ESC Score)

    Measured by blood samples and clinical data

    Time frame: 16 weeks

  3. Cardiovascular risk profile (ESC Score)

    Measured by blood samples and clinical data

    Time frame: 1 year

  4. Structural and functional cardiac changes

    Measured by echocardiography and CT coronary angiography

    Time frame: 16 weeks

  5. Structural and functional cardiac changes

    Measured by echocardiography and CT coronary angiography

    Time frame: 1 year

  6. Quality of life

    Measured by questionnaire SF-36

    Time frame: 16 weeks

  7. Quality of life

    Measured by questionnaire SF-36

    Time frame: 1 year

  8. Adherence to prescribed physical activity

    Measured by Mio Slice

    Time frame: 16 weeks

  9. Adherence to prescribed physical activity

    Measured by Mio Slice

    Time frame: 1 year

  10. Feedback from users

    Measured by interviews and feedback systems

    Time frame: 16 weeks

  11. Feedback from users

    Measured by interviews and feedback systems

    Time frame: 1 year

06

Study locations

1 site
  • Department of Circulation and Medical Imaging
    Trondheim, Norway
07

References and documents

Individual participant data

Plan to share: Yes — After the study ends all data from baseline and follow-up testing will be transferred to HUNT databank and made available for other researchers.

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03270202
Lead sponsor
Norwegian University of Science and Technology
Responsible party
Sponsor
First posted
Sep 1, 2017
Start date
Oct 1, 2017
Primary completion
Oct 17, 2018
Completion
Oct 17, 2018
Last update
Nov 30, 2018

Study contacts

Øystein Risa, phd
study director · Norwegian University of Science and Technology
Bjarne Martens Nes, phd
principal investigator · Norwegian University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion